Patients taking Kerendia saw significant reduction in cardiovascular death and hospitalization and urgent visits for heart ...

The US Food and Drug Administration (FDA) has granted 510(k) clearance for Tempus AI’s ECG-Low (ejection fraction) EF ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

The new Tempus software analyzes resting, non-ambulatory 12-lead ECG recordings to detect signs associated with having a low ...

Following priority review, the U.S. Food and Drug Administration approved Bayer's Kerendia (finerenone) for the treatment of ...

Researchers at the German Center for Cardiovascular Research (DZHK) have identified a key molecule involved in a form of ...

The FDA expanded the indication for finerenone (Kerendia) in heart failure (HF), drug manufacturer Bayer announced.

Approval of Kerendia was based on results from the Phase III FINEARTS-HF trial, which demonstrated statistically significant ...

The drug is now approved for treating people with an LVEF of at least 40%, with or without chronic kidney disease.

It's a new age for heart failure (HF) management, with growing appreciation for its "four pillars" of drug therapy, but also, it appears, the waning status of left ventricular ejection fraction ...

Part 1: Heart Failure: A Look at Low Ejection Fraction. Part 2: Exploring Heart Failure With Preserved Ejection Fraction. Part 3: Heart Failure With Reduced Ejection Fraction: Diagnosis and Evaluation ...

Half of the patients had diabetes, 73% had a left ventricular ejection fraction of 30% or less, 79% had a N-terminal prohormone of brain natriuretic peptide (NT-proBNP) level of at least 1000pg/mL ...